K Pharma (TSE:4896) Debt-to-Asset : 0.00 (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is K Pharma Debt-to-Asset?

K Pharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was 円0 Mil. K Pharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was 円0 Mil. K Pharma's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was 円2,972 Mil. K Pharma's debt to asset for the quarter that ended in Mar. 2024 was 0.00.

K Pharma Debt-to-Asset Historical Data

The historical data trend for K Pharma's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

K Pharma Debt-to-Asset Chart

K Pharma Annual Data

Trend

Dec21

Dec22

Dec23

Debt-to-Asset

K Pharma Quarterly Data
	Dec21	Dec22	Jun23	Sep23	Dec23	Mar24
Debt-to-Asset	Get a 7-Day Free Trial			-	-	-	-	-

Competitive Comparison of K Pharma's Debt-to-Asset

For the Biotechnology subindustry, K Pharma's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

K Pharma's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, K Pharma's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where K Pharma's Debt-to-Asset falls into.

K Pharma Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

K Pharma's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	3313.902
	=	0.00

K Pharma's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	2972.056
	=	0.00

K Pharma (TSE:4896) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

K Pharma Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of K Pharma's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

K Pharma (TSE:4896) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » K Pharma Inc (TSE:4896) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

7-7-7 Roppongi, Minato-ku, Tokyo, JPN, 106-0032

Website

https://en.kpharma.co.jp

K Pharma Inc is a company involved in Research, development, manufacturing, sales and marketing of pharmaceutical products and regenerative medicine products. It is involved in studying of iPs cells in regnerative medecine to treat neurological conditions such as cerebral infarction and SCI.

K Pharma (TSE:4896) Headlines

No Headlines